Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel

Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long‑term outcomes. Furthermore, patients with a first‑episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the l...

Descripción completa

Detalles Bibliográficos
Autores: Bernardo, Miquel, Díaz Marsá, Marina, González-Pinto, Ana, Martín Carrasco, Manuel, Pérez Sola, Víctor, Sáiz, Pilar Alejandra, Vieta, Eduard, Torrens, Marta, Arango, Celso, Crespo Facorro, Benedicto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/172856
Acceso en línea:https://hdl.handle.net/11441/172856
https://doi.org/10.1007/s40120-024-00700-y
Access Level:acceso abierto
Palabra clave:First‑episode psychosis
Treatment
Antipsychotic
Schizophrenia
Tolerability
Lur asidone
id ES_ed8eac25f09ddfbf46237c58bcdcb719
oai_identifier_str oai:idus.us.es:11441/172856
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panelBernardo, MiquelDíaz Marsá, MarinaGonzález-Pinto, AnaMartín Carrasco, ManuelPérez Sola, VíctorSáiz, Pilar AlejandraVieta, EduardTorrens, MartaArango, CelsoCrespo Facorro, BenedictoFirst‑episode psychosisTreatmentAntipsychoticSchizophreniaTolerabilityLur asidoneIntroduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long‑term outcomes. Furthermore, patients with a first‑episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low‑dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychoticnaïve and previously treated patients. Areas Covered: This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real‑world practice are provided Expert Opinion: In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.Springer London LtdPsiquiatríaCTS1086: Psiquiatría Traslacional2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/172856https://doi.org/10.1007/s40120-024-00700-yreponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésNeurology and therapy, 14 (1), e072348.https://link.springer.com/article/10.1007/s40120-024-00700-yinfo:eu-repo/semantics/openAccessoai:idus.us.es:11441/1728562026-06-17T12:51:07Z
dc.title.none.fl_str_mv Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
spellingShingle Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
Bernardo, Miquel
First‑episode psychosis
Treatment
Antipsychotic
Schizophrenia
Tolerability
Lur asidone
title_short Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_full Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_fullStr Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_full_unstemmed Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
title_sort Efficacy of lurasidone in first episode psychosis: patient phenotypes, dosage, and recommendations from an expert panel
dc.creator.none.fl_str_mv Bernardo, Miquel
Díaz Marsá, Marina
González-Pinto, Ana
Martín Carrasco, Manuel
Pérez Sola, Víctor
Sáiz, Pilar Alejandra
Vieta, Eduard
Torrens, Marta
Arango, Celso
Crespo Facorro, Benedicto
author Bernardo, Miquel
author_facet Bernardo, Miquel
Díaz Marsá, Marina
González-Pinto, Ana
Martín Carrasco, Manuel
Pérez Sola, Víctor
Sáiz, Pilar Alejandra
Vieta, Eduard
Torrens, Marta
Arango, Celso
Crespo Facorro, Benedicto
author_role author
author2 Díaz Marsá, Marina
González-Pinto, Ana
Martín Carrasco, Manuel
Pérez Sola, Víctor
Sáiz, Pilar Alejandra
Vieta, Eduard
Torrens, Marta
Arango, Celso
Crespo Facorro, Benedicto
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Psiquiatría
CTS1086: Psiquiatría Traslacional
dc.subject.none.fl_str_mv First‑episode psychosis
Treatment
Antipsychotic
Schizophrenia
Tolerability
Lur asidone
topic First‑episode psychosis
Treatment
Antipsychotic
Schizophrenia
Tolerability
Lur asidone
description Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long‑term outcomes. Furthermore, patients with a first‑episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low‑dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13–17 years). The efficacy and tolerability of lurasidone have been demonstrated in both antipsychoticnaïve and previously treated patients. Areas Covered: This paper provides a review and commentary regarding the use of lurasidone in patients with FEP. Case studies based on the authors’ clinical experiences with lurasidone in real‑world practice are provided Expert Opinion: In our experience, lurasidone has shown efficacy in FEP in different patient profiles, including those with psychoses associated with substance use disorders. Lurasidone provides clinically relevant benefits, especially in patients with affective symptomatology, and has a good tolerability profile.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/172856
https://doi.org/10.1007/s40120-024-00700-y
url https://hdl.handle.net/11441/172856
https://doi.org/10.1007/s40120-024-00700-y
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Neurology and therapy, 14 (1), e072348.
https://link.springer.com/article/10.1007/s40120-024-00700-y
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer London Ltd
publisher.none.fl_str_mv Springer London Ltd
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423515005878272
score 15,811543

Similares en LA Referencia